Program
valbenazine
Also written as “Valbenazine”, “NBI-98854” and “MT-5199”.
Its studies are mostly in Tardive Dyskinesia · Tourette Syndrome · Schizophrenia · Huntington Disease · Dyskinesias, led by 2 companies.
Drug pageValbenazine: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Neurocrine Biosciencesits history only | 272 open or running | phase 4since Oct 4, 2018 | Dec 21, 2010 | Apr 2028phase 3 · NCT06312189 |
| Tanabe Pharma | 10 open or running | phase 3since Jun 2, 2017 | Jun 2, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tanabe Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 2, 2017First study: phase 3 study in Tardive DyskinesiaFirst studyNCT03176771 · 256 enrolled · Japan
TargetBeta
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule
Other programs on SLC18A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| deutetrabenazinerule | Teva Pharmaceutical Industries | phase 4 | 12 |
Studies
The one study Tanabe Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03176771Tardive Dyskinesia · Japan | 3 | Completed | Sep 29, 2020 | 256 |
How it is read
Names in the registry
- “Valbenazine”, 15 entries
- “NBI-98854”, 13 entries
- “MT-5199”, 1 entry
- “NBI-98854 50 mg capsule”, 1 entry
- “NBI-98854 50 mg capsule once daily”, 1 entry
Conditions, from the studies’ own filings
- Tardive Dyskinesia, 10 studies
- Tourette Syndrome, 8 studies
- Schizophrenia, 4 studies
- Huntington Disease, 3 studies
- Dyskinesias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.